Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 5,901

Document Document Title
WO/2011/111694
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/108009
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/108692
Disclosed is an agent for preventing muscular atrophy, which has an excellent preventive effect on muscular atrophy and comprises a whey protein hydrolysate. Specifically disclosed is an agent for preventing muscular atrophy, which compr...  
WO/2011/109324
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2011/108009
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/108487
Disclosed is a new usage, with the goal of preventing skeletal muscle atrophy, for a specific polyphenol that inhibits the expression of a gene that causes muscular atrophy. Also disclosed is a composition which inhibits muscular atrophy...  
WO/2011/105572
A highly effective FAAH inhibitor, and especially a prophylactic or drug for severe pain, which can be administered orally, are needed. Provided is a pharmaceutical composition having as an active ingredient a novel heteroaryl derivative...  
WO/2011/102404
Disclosed are: a novel compound having an inhibitory activity on S1P lyase and capable of inducing the decrease in the number of lymphocytes or an isotope or pharmaceutically acceptable salt of the compound; and a pharmaceutical composit...  
WO/2011/101866
The present invention discloses a gastric retentive formulation (capsule or tablet) containing baclofen. Said formulation comprises an immediate and a sustained release part whereas the sustained release part is comprised in the core of ...  
WO/2011/096490
Disclosed is a prophylactic and/or therapeutic agent for rejection after transplant surgery and for diseases caused by immune system abnormalities, comprising a compound represented by formula (I) or a pharmacologically acceptable salt t...  
WO/2011/095893
A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibito...  
WO/2011/097456
The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild ...  
WO/2011/097500
The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.  
WO/2011/096484
A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises...  
WO/2011/097456
The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild ...  
WO/2011/096377
Disclosed is a novel low molecular weight compound that has an immunosuppressive effect. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, substituent...  
WO/2011/097500
The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.  
WO/2011/090062
Disclosed are a piperazine compound represented by formula (1) and a salt thereof. (In the formula, X represents CH or a N atom, R1 represents a C1-6 alkyl group; R2 represents any of a C1-6 alkyl group optionally having a substituted ba...  
WO/2011/081173
A tetracyclic compound represented by formula (I) (wherein Q represents -O- or the like; X represents CH or the like; R1 represents a lower alkyl group or the like; R2 and R3 independently represent a hydrogen atom or the like; and R4 an...  
WO/2011/078360
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR52 agonist activity and is useful as a prophylactic or therapeutic agent for schizophrenia and the like. (In the formula, ring Cy1 represents a five-membe...  
WO/2011/076811
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also rela...  
WO/2011/077252
The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalore adipic acid cocrystal, a 1:0.5 metaxal...  
WO/2011/078221
By making a search for many various compounds having inhibitory activity against IL-12/IL-23 production, provided are medicinal compositions that contain the compounds and therapeutic or prophylactic agents that contain the compounds and...  
WO/2011/077252
The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalore adipic acid cocrystal, a 1:0.5 metaxal...  
WO/2011/070539
Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C...  
WO/2011/071136
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.  
WO/2011/070541
Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C...  
WO/2011/068208
Disclosed is a novel treatment strategy for spinal and bulbar muscular atrophy (SBMA). Specifically disclosed is a therapeutic agent for spinal and bulbar muscular atrophy, which comprises triptan or a pharmacologically acceptable salt t...  
WO/2011/066656
Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase co...  
WO/2011/068171
Provided are compounds having prophylactic and/or therapeutic effect on chronic rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn diseases and ulcerative colitis, autoimmune diseases typified by psoriasi...  
WO/2011/065791
The present invention provides a composition comprising Astragali Radix extract as an active ingredient. The composition can increase body energy consumption and muscle metabolism. The present invention also relates to pharmaceutical and...  
WO/2011/064552
A construct suitable for delivery of a biologically active compound into cells, comprising: (d) a positively charged peptide; (e) a targeting-delivery peptide; and (f) the biologically active compound; wherein the positively charged pept...  
WO/2011/065791
The present invention provides a composition comprising Astragali Radix extract as an active ingredient. The composition can increase body energy consumption and muscle metabolism. The present invention also relates to pharmaceutical and...  
WO/2011/062253
Disclosed is a prophylactic and/or therapeutic agent for diseases associated with autoimmunity, immune deficiency diseases or neurodegenerative diseases, said prophylactic and/or therapeutic agent containing a novel fused pyrimidine deri...  
WO/2011/060488
The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof.  
WO/2011/059021
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...  
WO/2011/057350
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.  
WO/2011/058766
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or –SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have block...  
WO/2011/055944
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.  
WO/2011/056549
Dietary supplement compositions include an adaptogenic agent, an anti- inflammation agent, and an anti-oxidant. Methods for using dietary supplement compositions include (i) inhibiting, decreasing, and/or preventing delayed onset of musc...  
WO/2011/054659
The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particula...  
WO/2011/055944
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.  
WO/2011/050808
The invention relates to carbamylated erythropoietin for use in the treatment of Friedrich's ataxia.  
WO/2011/049053
It was discovered that myeloid cells, which occurs in the lamina propria of healthy animals and are highly positive to Gr-1, positive to CD11b and positive to CD11c, can induce T cell apoptosis and, in its turn, inhibit T cell activation...  
WO/2011/048350
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the pati...  
WO/2011/050262
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.  
WO/2011/047093
The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair dif...  
WO/2011/047093
The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair dif...  
WO/2011/041937
The use of hydroxytyrosol or an olive juice extract containing hydroxytyrosol for improving muscle differentiation and thus improving or maintaining the body's adaptation to exercise is disclosed. The pharmaceutical and nutraceutical com...  
WO/2011/038471
The technical subject matter of the present invention relates to a pharmaceutical composition that contains, as the active principle, substances obtained by extraction and purification of essential oils from a plant of the Alpinia genus....  

Matches 351 - 400 out of 5,901